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Abstract
Hepatitis C virus (HCV) infection is characterized by 
a high propensity for development of life-long viral 
persistence. An estimated 170 million people suffer 
from chronic hepatitis caused by HCV. Currently, there 
is no approved prophylactic HCV vaccine available. 
With the near disappearance of the most relevant 
animal model for HCV, the chimpanzee, we review the 
progression that has been made regarding prophylactic 
vaccine development against HCV. We describe the 
results of the individual vaccine evaluation experiments 
in chimpanzees, in relation to what has been observed 
in humans. The results of the different studies indicate 
that partial protection against infection can be achieved, 
but a clear correlate of protection has thus far not yet 
been defined.
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Core tip: With the near disappearance of the most 
relevant animal model for hepatitis C virus (HCV), the 
chimpanzee, we review the progression that has been 
made regarding vaccine development against this 
virus infection. An estimated 3 million people suffering 
from chronic hepatitis caused by HCV die each year. 
Currently, there is no approved vaccine available to 
prevent new infection. 
Verstrepen BE, Boonstra A, Koopman G. Immune mechanisms 
of vaccine induced protection against chronic hepatitis C virus 
infection in chimpanzees. World J Hepatol 2015; 7(1): 53-69 
Available from: URL: http://www.wjgnet.com/1948-5182/full/
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INTRODUCTION
Chronic hepatitis, caused by persistent infection with 
hepatitis C virus (HCV) is a major health threat world­
wide[1]. The number of  chronic HCV carriers is estimated 
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to be 170 million, about 1% to 2% of  the population. 
HCV is a 9600 nucleotide, single­stranded positive­
sense RNA virus belonging to the Flaviviridae. The open 
reading frame encodes for a large polyprotein with three 
structural proteins, Core (C), E1 and E2 that are linked via 
the presumed viroporin p7, to the nonstructural proteins 
NS1, NS2, NS3, NS5A and NS5B. The structural proteins 
form the viral particle, while the nonstructural proteins 
are involved in replication and maturation of  the virus 
particle. 
HCV infection is characterized by a high propensity 
for development of  life­long viral persistence. Only 
one in five acute infections is spontaneously eradicated, 
normally within the first six months after infection. 
During acute HCV infections, clinical symptoms are 
mild or absent. For that reason acute HCV infections 
are often not recognized. However, when acute HCV 
infection develops into a persistent infection, the majority 
of  the patients develop chronic hepatitis and over decades 
the virus causes subtle but cumulative hepatic damage. 
Ultimately this may lead either to cirrhosis, decompensating 
liver congestion or hepatocellular carcinoma. To give a 
sense of  the impact of  HCV infection on the health care 
system, it has been calculated that worldwide, 27% of  
the cases of  cirrhosis can be accounted for by HCV and 
population­based studies in the United States indicate that 
40% of  chronic liver disease is HCV related[2,3]. Overall, 
persistent HCV infection accounts for 3 million deaths 
each year[4]. 
TRANSMISSION
Transmission of  HCV occurs via blood­blood contact. 
Nowadays in the western world, the majority of  the new 
infections are associated with intravenous drug use, via 
sharing of  contaminated needles[5]. There are several 
examples of  drastically declined numbers of  new HCV 
cases, after the introduction of  surveillance programs 
and the distribution of  fresh disposable needles amongst 
intravenous drug users[6,7]. 
In other geographical regions, the mode of  trans­
mission is different. The situation is especially worrying 
in Egypt, where an estimated 12% of  the population is 
infected with HCV as a result of  an unsafe treatment­
procedure of  an endemic schistosoma infection in 
rural areas during the years 60­80 s of  the last century. 
Currently, the infrastructural organization of  the Egyptian 
health care system is still seen as, at least partially, 
responsible for ongoing transmission in the region[8]. 
Recently, World Health Organization (WHO) has declared 
the large reservoir of  chronic HCV carriers a serious risk, 
as tourism and migration contribute to spreading of  the 
virus to places outside the region.
HIGH PROPENSITY FOR CHRONIC 
INFECTION
There are 7 major genotypes of  HCV[9,10], each genotype 
consists of  a cluster of  different subtypes, and within 
each patient closely related quasi­species are present. 
The difference between two distantly related isolates can 
be as high as 30% at the nucleotide level[11]. Circulating 
quasi­species have the ability to mutate very quickly 
and can easily evade the immune system, and/or drugs 
that are used for treatment. In addition, the treatment 
protocol depends on the specific HCV genotype. Hence, 
it is difficult to develop a universal treatment regime for 
chronic HCV. 
As indicated by the rapid upregulation of  interferon­
stimulated genes (ISGs) in the host’s liver[12,13], HCV is 
present and recognized early after infection. However, 
differential HCV strains[14], the activation of  distinct 
molecular pathways[15], kinetics of  the ISG response[16] and 
even cellular composition of  the microenvironment in the 
liver[17] may be responsible for inadequate mobilization 
of  an effective immune response, ultimately leading to 
chronic infections. In this review we will focus on the 
role of  the adaptive immune system in clearance of  HCV 
infection, and place this in perspective of  HCV vaccine 
evaluation studies in chimpanzees. 
THERAPEUTIC DRUGS OR A VACCINE
For decades chronic HCV infection could only be treated 
with the broadly acting antiviral (pegylated) interferon, 
which was often accompanied by serious side effects 
and frequently not successful. Only in one out of  five 
patients, a so­called sustained virological response was 
achieved, meaning that HCV RNA had declined to 
undetectable levels in peripheral blood after treatment. 
In 1998, the nucleoside analogue ribavirin (RBV) was 
added to standard therapy­protocols and this improved 
treatment efficacy to about 40%[18­20]. 
The year 2011 can be considered as a breakthrough 
in the treatment of  chronic HCV infection. In that year, 
two direct­acting antiviral drugs (DAAs)­telaprevir and 
boceprevir­received regulatory approval and became 
available for patients. In combination with pegylated­
interferon and RBV, these NS3/4A protease inhibitors 
have shown marked efficacy in patients infected with 
HCV genotype 1. However, this combination was found 
to be less effective against other genotypes, and patients 
still experienced the severe side-effects characteristic for 
treatment with interferon and RBV. In addition, the genetic 
background of  the host can negatively affect treatment 
efficacy[21] and viral­resistance has been reported[22]. 
Regulatory approval of  NS5B­targeting DAAs, like 
sofosbuvir has leads to further improvements in the 
treatment of  chronic HCV infection. Not only do they 
have a better efficacy against genotypes other than genotype 
1, also duration of  the treatment is shorter[23,24]. In addition, 
these compounds can be administered orally and may 
possibly lead to interferon and ribavirin free treatment 
regimens.
More effective, more tolerable and safer treatment 
options however come with a price. Currently, oral 
DAA therapy is very expensive and therefore currently 
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not affordable in developing countries. Consequently, 
a prophylactic vaccine is imperative to contain HCV 
infection globally. 
CHIMPANZEES IN BIOMEDICAL 
RESEARCH
Humans and chimpanzees (pan troglodytes) share a 
common ancestor who lived approximately 30 million 
years ago, before the hominoid lineage split. Chimpanzees 
are humans’ closest living relatives with 98.9% identity 
at DNA level[25]. Since the 40 s of  the last century, 
chimpanzees have been used in the United States space 
program and later also in biomedical research. The 
colonies of  chimpanzees in research facilities were 
founded from animals that were imported from the wild 
in Western Africa. Soon, breeding programs assured 
enough offspring for experimental work and facilities 
became self­sustainable and no longer required import of  
chimpanzees from the wild. 
Public concerns about research with non­human 
primates, chimpanzees in particular, has eventually led 
to stop the use of  apes for HCV research in Europe, 
and a significant reduction of  the number of  animals 
used in the United States[26]. With the near disappearance 
of  the most relevant animal model for HCV, we review 
the progression that has been made regarding vaccine 
development against HCV describing the results in 
chimpanzees in relation to what has been observed in 
humans. To obtain a complete overview, a literature search 
was performed in PubMed combining the keywords 
chimpanzee(s) and hepatitis or HCV in combination with 
any of  the following keywords; vaccine(s), vaccination, 
immunization or immunized. Furthermore, there are only 
a limited number of  groups working on this subject and 
animals used can be identified by name or number and 
thereby tracked through the literature. 
CHIMPANZEES AND HCV RESEARCH
No doubt, chimpanzees have been the most important 
animal model to study HCV[27]. In the late 80 s, after it 
became clear that the majority of  blood borne chronic 
liver inflammations were not caused by hepatitis A or B 
virus, serum from a non­A­non­B hepatitis patient was 
inoculated into a chimpanzee[28]. From this chimpanzee, a 
cDNA bank was derived and in 1989 Michael Houghton 
and his coworkers at Chiron Inc. identified HCV as the 
main causative agent for non­A­non­B hepatitis[28]. 
Only chimpanzees and humans can be productively 
infected with HCV and this limited host range has seriously 
hampered HCV research. To date, the chimpanzee is 
the only validated animal model to study immunity 
associated with acute resolving infection, and protective 
immunity against HCV reinfection. Over the past 35 years, 
experimental infection of  chimpanzees with HCV has 
provided groundbreaking information regarding identi­
fication, characterization, transmission, early responses after 
HCV infection and triggering of  the innate as well as the 
adaptive immune system. Studies in chimpanzees have 
enabled us to identify immune mechanisms associated 
with viral clearance and chronic infection, critical for 
optimal prophylactic vaccine design. Subsequently, chim­
panzees were used to evaluate the efficacy of  vaccine 
candidates and vaccination strategies. 
PRIMARY HCV INFECTION IN 
CHIMPANZEES
To be able to study the effect of  a vaccine or vaccination 
strategy, it was necessary to identify the virological charac­
teristics of  HCV without any intervention. There are 
numerous reasons why it is difficult to study early events 
in HCV infection in humans. Firstly, in the vast majority 
of  the cases acute HCV infection is asymptomatic and 
patients therefore rarely seek medical attention. Secondly, 
collecting serial blood samples (and occasional liver­
biopsy material) from one individual during acute HCV 
infection is very difficult and, getting pre-exposed bio-
specimen from humans is complicated. Therefore, 
experimental inoculation of  chimpanzees was pivotal to 
study early events of  HCV infection.
In chimpanzees, similar to humans, intravenous 
exposure to HCV can either lead to a transient self-limiting 
infection or it may develop into a persistent infection[29]. In 
both humans and chimpanzees, viral RNA is detectable by 
reverse transcription polymerase chain reaction in plasma 
and liver tissue[30]. In addition, anti­HCV antibodies 
appear in peripheral blood of  both species 6 to 8 wk after 
HCV exposure[31,32]. In the majority of  human individuals, 
antibodies remain detectable in blood after viral clearance, 
while in chimpanzees sometimes a gradual loss of  HCV 
specific antibodies after viral elimination has been 
reported[30,33]. However, in humans, HCV specific cellular 
immune responses have been found in seronegative 
individuals, implying also there the loss of  HCV-specific 
antibodies after viral clearance[34­37].
Published data on cellular immune responses showed 
that HCV specific CD4 and CD8 T­cell responses in 
both humans and chimpanzees were weak after HCV 
infection. Spontaneous clearance was associated with 
somewhat stronger cellular responses compared to the 
individuals that became persistently infected[38­42]. Also 
in liver biopsies taken from HCV infected patients and 
chimpanzees CD4 and CD8 T­cells were observed[43­46] 
and relatively strong liver­associated T­cell responses 
were associated with viral clearance[46].
VIRAL PERSISTENCE IN HUMANS AND 
CHIMPANZEES
Based on antibody data, WHO estimates that 70% to 
90% of  the infections eventually develop into a persistent 
HCV infection. However, this percentage may be an 
overestimation as exposed seronegative individuals are 
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clearance provided some protection, characterized by 
reduced duration, peak virus load and reduced frequency 
of  development of  persistent HCV infection[47]. Under­
standing the underlying mechanisms through which a 
cleared HCV infection can contribute to protection against 
infection, or virus persistence, and the involvement of  the 
adaptive immune system has been an important research 
goal and pivotal for further HCV vaccine development. 
Since HCV­induced liver damage only leads to a fatal 
condition after decades of  ongoing immunopathogenesis, 
a vaccine that could achieve a similar rate of  protection 
from chronic infection as observed after a cleared 
infection, would already be of  great value. 
IMMUNE CORRELATES
Virus neutralizing antibodies
In 1994 it was already described that plasma components 
had an important role in protection against HCV in­
fection[67]. In a hallmark experiment by Farci et al[67], in vitro 
neutralizing capacity was determined by mixing infectious 
virus with heat inactivated plasma from the same patient 
and subsequently testing it for residual infectivity by 
inoculating the mixture into a naïve chimpanzee. Patient 
plasma collected 2 years after infection was able to prevent 
infection, while plasma collected 13 years after infection 
could not. At that time there was no in vitro system to 
confirm the presence of  neutralizing antibodies. However, 
simultaneous appearance of  envelope HCV specific 
antibodies in circulation 7 to 8 wk after infection[32] and 
mutations in viral RNA in the hypervariable region of  
E2[61,68­70] substantiated the involvement of  antibodies and 
demonstrated the flexibility of  the virus to escape from 
immune pressure through mutation. 
In vitro virus neutralization assays 
Subsequently, several strategies were used to develop a 
technique to measure neutralizing capacity of  antibodies 
in plasma of  HCV infected individuals. However, it was 
not until 2003 that HCV envelope based neutralization 
could be adequately determined. The HCV pseudoparticle 
(HCVpp) system[71] is based on the expression of  HCV 
envelope proteins on the surface of  retroviral particles. 
After co­transfecting 293T cells with plasmids encoding 
for HCV envelope protein, a retroviral backbone and 
green fluorescent protein/luciferase, HCVpp are being 
secreted into the culture medium. Next, after mixing 
serum and HCVpp, residual infectivity can be determined 
in hepatocellular carcinoma cells. The system is very 
flexible with regard to envelope sequences expressed that 
can be expressed on the viral surface. 
Because pseudoviruses may act different from HCV 
particles, a subgenomic replicon system was developed[72]. 
A robust cell culture­derived in vitro system was obtained 
when a replicon was constructed from a HCV genotype 
2a clone named JFH­1, which was isolated from a 
Japanese patient with fulminant hepatitis. Transfection of  
Huh­7 cells with the in vitro transcribed full length JFH­1 
not included in these calculations[34­37]. The documented 
percentages of  chimpanzees with persisting HCV in­
fection varies between different laboratories from 39% 
to 70%[33,47­49]. This wide range reflects the heterogeneous 
nature of  infection with HCV. Not only do virological 
differences, like genotype and dose of  infection, play a 
role but also genetic factors of  the host. In humans, the 
outcome of  HCV infection is associated with protective 
human leukocyte antigen alleles HLA­B27, HLA­B57 
and HLA-A3. And although the exact same major 
histocompatibility complex class Ⅰ alleles are not present 
in chimpanzees, homologues with similar peptide­binding 
characteristics have been identified in these animals[50]. 
Genome wide association studies have also shown genetic 
variation linked to the IL28B gene, whose product directly 
interferes with the antiviral interferon (IFN)­pathways and 
determines the ability of  patients to spontaneously resolve 
HCV infection[51,52]. In chimpanzees similar mechanisms 
may play a role[53]. 
Chimpanzee colonies in research facilities are not fully 
outbred. As a result higher frequencies of  certain MHC 
class Ⅰ molecules may be present in one facility compared 
to another facility. This so called “founder effect”, in 
combination with the fact that the total number of  human 
patients outnumbers the total number of  chimpanzees 
used in experimental infection studies may affect the 
percentage of  chronic infection per institute.
In conclusion, these contributing factors make it 
difficult to directly compare the percentage of  persistent 
infection between humans and chimpanzees. Maybe even 
more relevant is the difference in “life­style” regarding 
diet and alcohol intake. Also differences in HCV inocula, 
route and dose of  exposure may partly explain the 
difference. Similar factors may apply to distinct effects 
on changes in liver enzyme levels and progression to 
fibrosis. To our knowledge, it has never been documented 
that a chimpanzee developed liver fibrosis as a result of  
persistent HCV infection. 
HCV REINFECTION IN CHIMPANZEES
Documented reinfection studies in humans are relatively 
sparce[54­57]. Longitudinal analysis of  human intravenous 
drug users were performed, but results were inconclusive 
as to whether a previously cleared HCV infection induces 
functional immunological memory[55,56,58] that correlate 
with a shortened viremia and decreased HCV persistence. 
Important insights were obtained from chimpanzees in 
which experimental HCV re-exposure was studied in a 
controlled setting (genotype, dose and route of  infection) 
and longitudinal follow up studies could be performed[59­66]. 
Reinfection studies in chimpanzees have demonstrated 
that all of  the three possible outcomes: i.e., protection 
from infection[63,64], protection from viral persistence[59,63­65] 
or persistent HCV infection[59], can occur. 
Pairwise comparison of  virological parameters 
during primary infection in naïve chimpanzees vs animals 
that were rechallenged[47] showed that previous HCV 
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resulted in the secretion cell­culture­derived infectious 
HCV particles (HCVcc)[73]. Similar to the HCVpp system, 
the HCVcc assay is based on the binding of  antibodies to 
HCV envelope expressing particles before testing residual 
infectivity on hepatocellular carcinoma cells. Because 
of  the high specificity of  the neutralizing antibodies, 
this system did not suffice for measuring neutralization 
of  genotype 2a based HCVcc and intergenotype clones 
were constructed[74]. Unfortunately, replacing the JFH­1 
envelope proteins by envelopes from other genotypes 
resulted in less efficient production of  viral particles. 
Nevertheless, both HCVpp and HCVcc techniques 
have been shown to be very valuable in improving the 
understanding of  viral entry and antibody neutralization[75].
Antibody correlates
HCV specific antibodies generated during the acute phase 
of  the infection are mainly directed against linear epitopes 
within structural and non­structural viral proteins, 
while neutralizing antibodies have been mapped to 
conformational epitopes within the E1 and E2 envelope 
proteins[76­82]. While most neutralizing antibodies are 
rather strain specific[82­84], broadly neutralizing antibodies, 
antibodies that recognize epitopes that are highly 
conserved between genotypes, have also been described 
for E2[83,85,86]. 
Only for glycoprotein E2, specific targets for receptor 
binding have been identified: CD81 and scavenger 
receptor class B member 1 (SRB1) and coreceptors[87]. 
Neutralizing antibodies directed against domain Ⅰ and 
Ⅲ of  E2 interfere with its binding to CD81, while 
neutralizing antibodies directed against hypervariable 
region 1 (HVR­1) interfere with the binding of  E2 to 
SRB1. 
In humans, early induction of  strain specific neu­
tralizing antibodies was found to be associated with 
spontaneous recovery[88,89]. Unfortunately, in most cases 
these antibodies are only formed during the chronic 
phase of  the infection, when viral clearance is more 
difficult to achieve. Nonetheless, these antibodies may 
exert immune pressure that could potentially lead to 
decreased viral fitness. 
The paradigm that neutralizing antibodies play a less 
prominent role in chimpanzees compared to humans, 
is mostly based on data collected by Logvinoff  et al[89]. 
In patient H, from which HCV clone H77 was derived, 
strain specific neutralizing capacity was observed 7 
wk post infection[89], while in the majority of  humans 
neutralizing antibodies are observed after 100 wk post 
infection[89]. In chimpanzees infected with H77, specific 
neutralization was detected only 15 to 20 wk post 
infection. This relatively late detection in chimpanzees 
may possibly be explained by the fact that the HCVpp 
were based on the exact same H77 sequence that was 
present in patient H. After inoculation of  the RNA clone 
H77 in chimpanzees, it may however have rapidly adapted 
to its new host and therefore be slightly different from 
the original H77 clone, showing decreased HCVpp­H77 
neutralizing capacity.
ROLE OF T-CELL RESPONSES
Since these early studies, it has been reported that 
hypogammaglobulinaemic patients have the ability to 
spontaneously clear HCV infection[90]. Hence, T­cell 
responses may have contributed to the protection against 
HCV challenge described above. Furthermore, antibody­
mediated depletion experiments in chimpanzees showed 
that when CD8 T­cells were depleted, virus replication 
was prolonged despite the presence of  memory CD4 
T­cells and HCV was only cleared after recovery of  HCV­
specific CD8 T-cells in the liver[66]. But on the other hand, 
CD4 T­cells were required for a complete control of  HCV 
replication despite the presence of  functional intrahepatic 
CD8 T­cells[91]. Similarly, the association between HLA­
class Ⅰ molecules HLA­A*03, HLA­B27 and HLA­B57 
and class Ⅱ molecules HLA­DRβ1*0101, HLA­DRB1*0401, 
HLA­DRB1*1101 and HLA­DRB1*0301, and HCV 
clearance, emphasizes the role of  respectively, CD8 and 
CD4 cells (reviewed in[21]). 
T-CELL RESPONSE PATTERNS
HCV specific T­cell responses have been reviewed in 
detail elsewhere[92­95]. As schematically depicted in Figure 
1, four different scenarios can be used to describe HCV 
specific adaptive immune responses in relation to HCV 
clearance or viral persistence: (1) a spontaneous clearance 
of  HCV infection, associated with early and effective T­cell 
responses (Figure 1A). The most important characteristics 
of  this successful cellular immunity against HCV are 
relatively strongly expanding T-cells that are fully functional 
with respect to cytolytic capacity, reflected by granzyme 
and perforin secretion, or cytokine production[96­104]; (2) 
Transient immune control (Figure 1B) and ensuing viral 
escape that may be the result of  either immune mediated 
viral selection or an exhausted immune response. Immune 
pressure may drive the generation of  virus variants in 
which relevant T­ or B­cell epitopes are mutated and 
therefore no longer recognized when they are presented on 
infected hepatocytes. During tolerance and/or exhaustion 
on the other hand, immune modulatory mechanisms 
result in dysfunctional T­ or B­cells but with an intact 
and specific T- (or B-) cell receptor on its surface[105]; (3) 
Chronic or persistent HCV infection occurs when T­cells 
are not fully differentiated into functional effector cells 
(Figure 1C) or no neutralizing antibodies are produced; 
and (4) Protection of  chronic HCV infection by vaccine­
induced immune responses. Hypothetically, vaccine­
induced neutralizing antibodies may prevent infection 
while functional HCV specific T­cells may protect from 
chronic infection (Figure 1D). 
VACCINES 
Several prophylactic vaccine efficacy experiments have 
been performed in chimpanzees[106­120]. Relevant infor­
mation regarding vaccine components, strategy, adjuvants, 
genotype of  the vaccine and the challenge virus and the 
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challenge outcome are summarized in Table 1. We will 
first focus on vaccine candidates that were developed 
for the induction of  neutralizing antibody responses to 
protect against infection. Subsequently, vaccine strategies 
aiming to induce cellular immune responses to control 
viral infection are discussed.
The envelope glycoproteins as vaccine antigens
Structure and function of  envelope glycoproteins: As 
stated above, HCV envelope glycoproteins E1 and E2 are 
key determinants for HCV entry. They mediate receptor 
binding, and the ensuing fusion process between the viral 
envelope and an endosomal host cell membrane[121,122]. E1 
and E2 are heavily glycosylated proteins with a C­terminal 
transmembrane domain anchored in the lipid envelope of  
the virus particle. On the surfaces of  HCV particles, the 
envelope glycoproteins are present as large disulphide­
linked oligomers[123]. 
Little is known about the structure of  the E1E2 heter­
odimer, but a proposed model of  the E2 ectodomain[124] is 
comprised of  three separate domains (DⅠ; described to 
be a discontinuous region containing the CD81 binding 
site, DⅡ; predicted to possess the fusion peptide and D
Ⅲ; described to contain antigenic neutralization epitopes 
and to be involved in heterodimerization with E1[125]), and 
three immunogenic HVR1 (384­411), HVR2 (473­480) and 
HVR3; (431­466).
E1 is even less well characterized, and may be important 
for the correct folding of  E2[126] and the E2 mediated 
fusion process[127]. E1 may also be involved in controlling 
virus assembly[87]. The structure of  the E1E2 heterodimer 
is still largely unresolved. Both the functional characteristics 
of  E1E2 and the detection of  neutralizing antibody 
responses against these proteins make them obvious 
candidates as vaccine­antigen. Long before the presence of  
HCV neutralizing antibodies was actually confirmed, the 
Figure 1  Schematic overview of the different causes of hepatitis C virus infection in relation to modulation of the adaptive immune response. A: Viral 
clearance. Viral RNA (red line) is normally detected in blood within 1-2 wk after exposure. The virus load will increase until the emergence of HCV specific CD4 
(yellow line) and CD8 T-cell (green line) responses 4 to 8 wk after infection[98]. Ideally, strain specific neutralizing antibodies (blue line) are present around the same 
time[88,89]. After viral elimination, antibody responses can either remain present or decrease to undetectable levels. Memory T-cells remain usually present and can be 
detected by in vitro assays; B: Transient control. After the initial peak viremia (red line), T-cell responses emerge and virus load decreases but remains detectable in 
serum. CD8 T-cells (green line) remain detectable but CD4 T-cell (yellow line) responses decrease to low levels. There appears to be a constant battle between virus 
and the immune system. De novo escape variants are able to evade the T and B-cell responses but at the same time lose viral fitness. When effective T and B-cell 
responses contract because the correct epitopes are no longer present, the virus “mutates back” to a more fit variant and virus load may increase again. Thinner lines 
of the adaptive immune responses represent decreased functionality of CD4 (yellow), CD8 T-cell (green) and antibodies (blue); C: Failed control leading to persistent 
infection; After the initial peak viremia, T-cell responses emerge and virus load decrease to lower levels but virus remains detectable in serum. T and B cells are 
functionally impaired or present in too low numbers to efficiently eliminate the virus. The virus remains present at steady state levels. Thinner lines of the adaptive 
immune responses represent decreased functionality of CD4 (yellow), CD8 T-cell (green) and antibodies (blue); D: Vaccine induced protection model. Vaccine-
induced broadly neutralizing antibodies are present at the time of exposure and prevent virus production by infected hepatocytes. The hepatocytes that are infected 
are successfully eliminated by cytolytic T-cells in the liver. 
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correlated with vaccine induced antibody responses 
(Table 1). The other two vaccinees showed overall 
lower viremia compared to the control animals and only 
minimal transient elevation of  the liver enzyme alanine 
aminotransferase levels in plasma. From this experiment 
it was concluded that protection from­chronic­HCV 
infection was achieved by gpE1/gpE2 vaccination and the 
level of  protection correlated with the level of  antibodies 
directed against gpE1/gpE2. 
During this vaccine­study, the lack of  an efficient in 
vitro culture system made it impossible to determine the 
neutralizing capacity of  the vaccine­induced antibodies. 
Retrospective analysis performed by Meunier et al[128] 
demonstrated robust neutralization in four out of  five of  
the protected animals. However, since one of  the protected 
animals showed only minimal HCVpp neutralizing 
capacity, and another animal with high neutralizing titers 
was not protected, neutralizing antibody responses alone 
cannot fully explain the results. Furthermore, vaccine 
antigens were derived from the same HCV strain that was 
used for the challenge. 
Dahari et al[47] reported the results from 21 animals 
immunized with gpE1/E2. Included in these numbers 
were the seven animals described by Choo et al[106]. From 
the 14 animals that received a similar recombinant protein 
vaccine 12 vaccinees resolved HCV infection while 2 
animals developed persistent HCV infection[47,107,119].
In conclusion, while very promising results have been 
obtained with this vaccine candidate, there is some note 
of  caution since these results could not be reproduced. 
Induction of  cross neutralizing antibodies: At the 
time of  these experiments, heterogeneity in the envelope 
regions became evident, and it was assumed that 
multivalent vaccines were required to provide protection 
to heterologous virus stains. In order to broaden the 
immune response, and offer protection against a wider 
range of  HCV isolates, Esumi et al[108] used truncated E1 
and E2 glycoproteins produced in insect cells together 
with HVR­1 peptides from a different HCV isolate and 
immunized one chimpanzee. The vaccine, delivered in 
Freund’s (in)complete adjuvant, induced E1 and E2 
specific humoral responses, but only a low antibody titer 
against HVR­1. Upon challenge with HCV#6, the animal 
showed a transient peak of  HCV RNA, which in view of  
the low propensity of  this virus to cause chronic infection 
implies that the vaccine did not confer protection. 
E1 neutralizing capacity: Because these HCV­envelope 
protein vaccines were based on the E1E2 heterodimer, 
the role of  the individual glycoproteins could not be 
determined. Only recently, the gpE1 and a gpE2 lacking 
the HVR­1 were evaluated separately[109]. In two animals 
immunized with gpE1 HCV neutralizing antibodies were 
induced and after a heterologous HCV­1b challenge, 
both animals were able to resolve HCV infection shortly 
after challenge. In contrast, the two E2 delta HVR­1 
immunized animals showed no HCVpp 1b neutralizing 
capacity, and despite the presence of  E2 specific cellular 
responses both animals were not protected from chronic 
HCV infection. For the first time, this study showed that 
E1 neutralization can be achieved and has protecting 
potential. Possibly, epitopes within E1 are masked 
when administered as a heterodimer and may therefore 
have been missed until now. However, the exact role 
of  E1 during the cell entry process needs to be further 
elucidated.
New insights in the role of  E1 indicate that a better 
understanding of  the interaction between E1 and E2 as 
well as the exact mechanisms of  virus/receptor interaction 
and cell entry are needed. 
Vaccine strategies for induction of protective T-cell 
responses
Although traditionally most vaccination strategies have 
relied on the induction of  neutralizing antibody responses, 
the emergence of  human immunodeficiency virus (HIV) 
and the realization that cellular immune responses are 
important in suppressing replication of  this virus has 
boosted the development of  new vaccine strategies 
for the induction of  effective T­cell responses. The 
HCV vaccine research has greatly benefited from these 
developments and modeled their experimental vaccines 
on the knowledge gained in the HIV-field. 
DNA vaccines encoding for HIV antigens have been 
proven efficient in the induction of  HIV specific T-cell 
responses[129]. In the year 2000, Forns et al[110] performed a 
proof  of  principle experiment in two chimpanzees, using 
a DNA plasmid encoding for surface-expressed E2. One 
animal developed antibodies directed against E2 and 
HVR­1, while the other animal had only very low levels 
of  E2 specific antibodies. However, no HCV specific 
T­cells could be detected. Nonetheless, upon challenge 
with the heterologous HCV, both vaccinees resolved 
HCV infection, while the control animal developed 
a persistent HCV infection. From this experiment it 
appears that DNA immunization can provide protection 
against infection, although the underlying mechanism is 
still unclear. 
Virus-like particles: Delivery of  antigens in the form 
of  virus­like particles has been described as an efficient 
strategy to elicit T­cell responses[130]. This was evaluated 
in a study in chimpanzees, by giving four immunizations 
with HCV­like particles[111] consisting of  the structural 
proteins Core, E1 and E2, in AS01B adjuvant. All four 
chimpanzees showed broad and strong T­cell responses, 
determined by IFN Enzyme­Linked ImmunoSpot 
(ELISPOT) and proliferation assay, in peripheral blood. In 
the liver antigen specific CD4 as well as CD8 T-cells were 
observed, comparable in magnitude to the blood. All four 
animals were able to control an intravenous challenge with 
HCV clone CG1b within 12 wk. 
Multicomponent prime-boost vaccine strategies: 
Experience from the HIV vaccine field has shown that 
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the induction of  cellular immune responses is greatly 
enhanced when two different vaccine modalities are given 
in a so­called “prime­boost” combination[131]. 
A multicomponent prime­boost vaccine strategy was 
evaluated by Rollier et al[112] using the relatively conserved 
regions, Core and NS3, in combination with the variable 
E1 and E2, as vaccine antigens to induce an immune 
response against a broad range of  HCV variants. DNA 
plasmids expressing the individual antigens were used 
to prime the immune system and subsequently three 
recombinant protein immunization were given as boosts. 
Both immunized animals developed strong humoral as 
well as strong cellular responses. Animals were challenged 
with a heterologous HCV­1b strain and in contrast to the 
control animal, both vaccinees suppressed virus replication 
to below the detection limit early after exposure. However, 
in one vaccinee the virus kept reappearing in plasma at 
very low levels while no evidence for HCV replication 
could be observed in the other chimpanzee. 
Puig et al[113] aimed to induce neutralizing antibodies 
by giving a prime with DNA encoding for E1E2 in 
combination with HVR peptides in ALUM adjuvant. 
The responses were boosted with recombinant E1E2 
heterodimer in RIBI (squalene which is emulsified with 
saline containing Tween 80)[113]. Strong HVR­1 specific 
antibody responses were observed in peripheral blood and 
cellular proliferative responses and cytokine production 
were found in the liver. Despite these vaccine­induced 
responses, the animal became persistently infected after 
exposure to an homologous challenge strain. Compared 
to the naïve non-vaccinated control animal, a delay in the 
peak of  virus replication was observed, but not a reduced 
viremia. 
In another experiment performed by the same research 
group, priming with DNA plasmids encoding HCV­NS3, 
NS5A or NS5B, followed by a booster immunization 
with recombinant vaccinia constructs expressing the same 
HCV proteins, resulted in strong T­cell responses. After 
experimental HCV exposure, initially virus replication was 
controlled. However, the virus reemerged. Losing immune 
control coincided with emergence of  new virus variants 
and the loss of  CD4 T­cell recognition[114].
In a similar DNA prime modified vaccinia virus 
(MVA) boost strategy, but now directed against HCV 
core­E1­E2 and NS3, strong and broad T­ and B­cell 
responses were reported[115]. However, despite strong 
humoral responses, no virus neutralizing capacity was 
found and after challenge with HCV­1b, all four animals 
showed acute viremia. Only one animal was able to 
control virus replication to undetectable levels. The other 
three animals became chronically infected. The vaccine 
induced vigorous T-cell responses as reflected by strong 
proliferation and HCV specific IFNγ, interleukin­2 (IL­2) 
and IL­4 cytokine responses. Retrospectively, vaccine 
induced T­cell responses were analyzed in more detail. 
It was found that, although the vaccine elicited NS3 
specific cytokine producing CD4 and CD8 T­cells in 
all four vaccinees, only in the chimpanzee that cleared 
HCV infection, CD8 T­cells were found to have cytolytic 
capacity[132]. Interestingly, the animals that became 
chronically infected had higher mRNA expression levels 
of  exhaustion markers programmed cell death protein 
1 (PD-1), cytotoxic T-lymphocyte-associated protein 4 
(CTLA-4) (Figure 2) and indoleamine 2,3-dioxygenase 
in the liver, suggesting the induction of  T­cells with 
regulatory functions that might have prevented formation 
of  a cytotoxic T-cell response[115]. 
In 2008, a replicating recombinant vaccinia virus 
(rVV) vaccine; PolyVax (rVV-HBV-HCV) was evaluated 
in chimpanzees[116]. After immunization with PolyVax the 
animals were exposed to HBV and after resolution of  
the HBV infection, they were boosted with HCV­rVV, 
expressing HCV-1b based E1, E2, p7, NS2 and NS3. To 
assess the efficacy against HCV infection, animals were 
intravenously exposed to 2.5 CID50 of  a homologous 
HCV strain. Unfortunately, this challenge was not successful 
and 17 wk later a second challenge was performed with 
the same inoculum with 24 CID50. After peak viremia, 
viral titers declined to non­detectable levels within 4 wk 
in all four vaccines while two controls became persistently 
infected. Eighteen months after the initial HCV clearance a 
multigenotype rechallenge was performed. Only one animal 
was able to clear infection while in three other animals, 
genotype HCV-1a remained detectable in plasma. PolyVax 
transiently induced HCV neutralizing antibodies. However, 
these were not present at the time of  HCV exposure. On 
the other hand long lasting IFNγ secretion and proliferative 
responses were observed after PolyVax immunization 
and these cellular responses were boosted by HCV­rVV. 
To what extend these responses may have contributed to 
control of  virus replication after the second challenge is 
difficult to establish due to possible contribution of  the first 
2.5 CID50 HCV exposure. 
Adenoviruses are efficient vehicles for gene transfer 
and have a natural tropism for the liver[133], the site of  
HCV replication and therefore a good candidate for 
the delivery of  HCV antigens. Youn et al[117] described 
a vaccine study with 6 chimpanzees, in which animals 
were primed with DNA encoding for HCV­Core, E1, 
E2, NS3-5 with three out of  six animals receiving an 
additional plasmid encoding for IL­12 to promote the 
development of  IFNγ producing Th1 cells. The prime 
was followed by an immunization with replication 
incompetent adenovirus expressing the same HCV 
antigens. Strong vaccine induced humoral as well as 
cellular responses were measured in proliferation assays, 
E2 specific enzyme­linked immunosorbent assay and 
neutralization assays. In the animal with the strongest 
responses at the day of  challenge, no HCV RNA could be 
detected. All other animals had a delayed and lower peak 
virus load and four animals became persistently infected.  
While viral vectors typically induce high cellular 
immune responses, they have the disadvantage that anti­
vector responses are formed that limit their repeated 
application. To circumvent this problem, Folgori et al[118] 
used two different types of  replication defective adenoviral 
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vectors for two subsequent booster immunizations[118]. 
For an optimal booster effect, the adenoviruses were 
selected based on low seroprevalence in humans and 
little or no immunological cross­reactivity between the 
two types. Both prime and booster immunizations were 
directed against the non structural proteins NS3 to NS5B. 
Upon HCV challenge, the immunized animals showed 
a reduction of  acute viremia, which coincided with 
expansion of  HCV specific CD8 T-cells in peripheral 
blood as well as the liver. In 4 out of  5 immunized 
animals, virus load was reduced to undetectable levels, 
while in the control group 3 out of  5 animals cleared the 
infection. 
Similar results were reported in a study, where 
chimpanzees received a DNA prime followed by an adeno­
virus boost, both expressing NS3-5B + pIL-12[134]. One 
animal cleared the infection while the other became 
persistently infected. Evidence was found for the 
selection of  escape mutants that evaded vaccine induced 
T­cells. Comparison of  the nucleotide sequence of  the 
circulating viruses in the two immunized animals and the 
control animal, showed a nonsynonymous/synonymous 
ratio indicative for positive selection. The exact same 
immunization strategy was then used to vaccinate two 
additional chimpanzees[120] and again one chimpanzee was 
able to control the infection early after challenge while in 
the other animal the virus persisted and the animal became 
chronically infected. 
In conclusion, all immunization strategies that were 
evaluated in chimpanzees induced either humoral or 
cellular immune responses, or both. As nicely shown in 
the meta analysis performed by Dahari et al[47], compared 
to non­immunized animals, vaccinees generally showed 
reduced virus replication in the early phase of  the 
infection, although complete protection from infection 
was rare. In addition, the analysis showed that the 
proportion of  HCV persistence in vaccinees (28.3%) is 
much lower compared to 61.9% observed in the control 
animals that were included[47]. 
VACCINE INDUCED T-CELL RESPONSES 
IN BLOOD AND PREDICTION OF 
OUTCOME
A direct comparison between the individual chimpanzee 
experiments is not always possible because of  disparity in 
experimental design, vaccine-antigens, vaccine regimen, 
heterologous or homologous challenge virus and challenge 
dose. Also, various methods have been used to assess 
the magnitude of  vaccine induced T­cell responses. For 
instance for the quantification of  cytokine production, real-
time quantitative polymerase chain reaction, intracellular 
cytokine staining and ELISPOT assays have been used, 
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which do not necessarily yield the same answer. Despite 
these differences, important conclusions can be drawn 
on immune regulatory mechanisms that are potentially 
involved in HCV clearance. 
Clearly, neither the magnitude of  the vaccine induced 
immune responses nor the breadth of  the responses 
could predict the protective effect of  a vaccine within 
one experiment. There is a striking heterogeneity in 
vaccine­induced responses between individuals. This not 
only reflects the genetic variation of  a population but also 
differences in pathways as well as regulatory mechanisms 
of  T­cell responses, similar to the variation observed in 
human patients suffering from HCV infection[135]. Larger 
study groups would be needed to cover this diversity, 
but the special nature of  the animals and the high costs 
involved, precludes larger experiments. 
As an example, in the Folgori study, where a DNA-
prime was followed by an adenovirus boost expressing 
the same antigens, it was not the animal with strong and 
broad vaccine-induced cytotoxic T-cell (CTL) responses 
that was protected from infection[118]. On the other hand 
the vaccinee with the lowest CTL response was the one 
animal that became persistently infected. Youn et al[117] 
described an association between E2­specific adaptive 
immunity and protection from (chronic) infection. 
However, in other experiments E2 was not identified as 
the key­antigen for protection against chronic infection. 
ESCAPING VACCINE INDUCED 
IMMUNITY 
HCV is notorious for its ability to mutate, resulting 
in development of  different de novo variants that are 
generated under immune pressure and result in escape 
from T and B­cell responses. Data generated by Lavillette 
et al[127] describe two patterns of  progressive emergence 
of  neutralizing antibodies, which were correlated with a 
fluctuating decrease in virus load, leading to control of  
virus replication and ultimately viral clearance. These data 
strongly suggest escaping functional B­cell responses is 
at least one of  the mechanisms for viral persistence. In 
addition, escape mutations have been described for both 
CD4[114] and CD8 T­cell[118] epitopes. Vaccine induced 
immune escape is therefore of  great concern. 
On the positive side, mutations induced by immune 
pressure can lead to a reduction in viral fitness that could 
potentially limit viral persistence. It was demonstrated 
that immune pressure induced changes of  non­structural 
regions can be lethal to the virus[136], while specific changes 
in envelope glycoproteins may have serious implications 
in selective outgrowth[137], virus entry and sensitivity to 
neutralization[138]. 
OTHER MECHANISMS TO EVADE 
VACCINE INDUCED IMMUNITY 
Apart from generation of  escape mutants, HCV may 
evade immune pressure by modulating immune responses. 
HCV specific T-cells with an exhausted phenotype in 
terms of  loss of  CD127 expression, cytokine expression 
and increased levels of  the inhibitory markers PD­1 and 
CTLA­4 have been described[139­141] (Figure 2). Moreover, 
the negative immune modulator Tim­3, LAG­3, CD160 
and 2B4 have been associated with exhausted HCV 
specific T-cells[139,142,143]. 
Also active suppression of  HCV­specific T­cell 
responses by regulatory T­cells or by the immunosuppressive 
cytokines IL­10 and transforming growth factor­β have 
been described[144]. The contribution of  each of  these 
immuno­regulatory mechanisms during HCV persistence 
varies between individual patients and also synergistic 
effects were found[135]. Restoration of  dysfunctional HCV­
specific T-cell responses by blocking inhibitory molecules 
temporarily restored anti­HCV T­cell responses resulting 
in a transient drop in virus load[143,145­147]. Combining the 
recovery of  functional T­cells with a boost of  T­cell 
responses will be of  interest as a therapeutic vaccine 
strategy. 
Natural killer (NK) cells play an important role 
during HCV infections[148] because of  their potential to 
lyse infected hepatocytes via antibody dependent cellular 
cytotoxicity. However, because NK cell function has not 
been studied in the context of  vaccine induced clearance 
of  HCV in chimpanzees, this is not documented.
Some of  the prophylactic vaccine candidates and 
regimen that were found beneficial in chimpanzees 
have been, or are currently, tested in humans. For two 
HCV­envelope vaccines, E1/E2[119] and E1[149], T­cell 
and antibody responses in healthy volunteers were 
comparable to the responses found in chimpanzees. 
Despite these promising results, the development of  both 
candidates is currently on hold.
Both adenovirus and MVA were successful as vaccine 
delivery vehicles in chimpanzees and both platforms 
have advanced to human trails. To overcome vector 
specific immunity much effort was put into the design 
of  even less immunogenic vectors or, when multiple 
immunizations are required, the design of  immunization 
protocols with different serotypes of  the vector. MVA 
and adenovirus based vaccines are currently incorporated 
in­mainly­therapeutic vaccination strategies in chronically 
infected patients.
CONCLUSION AND FUTURE VACCINE 
PERSPECTIVES
Studies in chimpanzees have provided important insights 
into the efficacy of  different vaccine strategies and 
provided evidence for the central role of  neutralizing 
antibodies in obtaining protection against infection. While 
most vaccine candidates that induce cellular immune 
responses, do not protect from infection they do lead to 
reduced viremia in the acute phase of  the infection and 
reduce the risk for development of  chronicity. The current 
challenge is to translate this newly acquired knowledge 
into an efficient prophylactic HCV vaccine that protects 
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from chronic HCV infection. 
Due to further restrictions on the use of  chimpanzees 
for biomedical research, future evaluation of  a new vaccine 
candidates or strategies in these apes will be severely 
limited. We have summarized the work performed so 
far, discussing the different immunization strategies used 
and types of  immune response induced. Although partial 
protection, defined as decreased chance to develop chronic 
HCV infection, can be achieved by immunization, a clear 
correlate of  protection has not yet been established. 
Further studies are required and have to be based to a large 
extent on clinical trials.
ACKNOWLEDGMENTS
The authors would like to thank Henk van Westbroek 
for the illustrations and Thea de Koning for editing the 
manuscript.
REFERENCES
1 Gravitz L. Introduction: a smouldering public-health crisis. 
Nature 2011; 474: S2-S4 [PMID: 21666731 DOI: 10.1038/474S2a]
2 Williams I. Epidemiology of hepatitis C in the United States. 
Am J Med 1999; 107: 2S-9S [PMID: 10653448]
3 Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. 
The contributions of hepatitis B virus and hepatitis C virus 
infections to cirrhosis and primary liver cancer worldwide. 
J Hepatol 2006; 45: 529-538 [PMID: 16879891 DOI: 10.1016/
j.jhep.2006.05.013]
4 A dozen good ideas to battle hepatitis. Lancet 2008; 371: 1637 
[PMID: 18486721 DOI: 10.1016/S0140-6736(08)60699-6]
5 Valdiserri R, Khalsa J, Dan C, Holmberg S, Zibbell J, Hol-
tzman D, Lubran R, Compton W. Confronting the emerging 
epidemic of HCV infection among young injection drug users. 
Am J Public Health 2014; 104: 816-821 [PMID: 24625174 DOI: 
10.2105/AJPH.2013.301812]
6 Van Den Berg C, Smit C, Van Brussel G, Coutinho R, Prins 
M. Full participation in harm reduction programmes is 
associated with decreased risk for human immunodeficiency 
virus and hepatitis C virus: evidence from the Amsterdam 
Cohort Studies among drug users. Addiction 2007; 102: 
1454-1462 [PMID: 17697278 DOI: 10.1111/j.1360-0443.2007.01
912.x]
7 Abdul-Quader AS, Feelemyer J, Modi S, Stein ES, Briceno 
A, Semaan S, Horvath T, Kennedy GE, Des Jarlais DC. 
Effectiveness of structural-level needle/syringe programs 
to reduce HCV and HIV infection among people who inject 
drugs: a systematic review. AIDS Behav 2013; 17: 2878-2892 
[PMID: 23975473 DOI: 10.1007/s10461-013-0593-y]
8 Yahia M. Global health: a uniquely Egyptian epidemic. Nature 
2011; 474: S12-S13 [PMID: 21666728 DOI: 10.1038/474S12a]
9 Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, 
Feinstone S, Halfon P, Inchauspé G, Kuiken C, Maertens 
G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, 
Penin F, Sablon E, Shin-I T, Stuyver LJ, Thiel HJ, Viazov 
S, Weiner AJ, Widell A. Consensus proposals for a unified 
system of nomenclature of hepatitis C virus genotypes. 
Hepatology 2005; 42: 962-973 [PMID: 16149085 DOI: 10.1002/
hep.20819]
10 Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, 
Stapleton JT, Simmonds P. Expanded classification of 
hepatitis C virus into 7 genotypes and 67 subtypes: updated 
criteria and genotype assignment web resource. Hepatology 
2014; 59: 318-327 [PMID: 24115039 DOI: 10.1002/hep.26744]
11 Simmonds P. Genetic diversity and evolution of hepatitis 
C virus--15 years on. J Gen Virol 2004; 85: 3173-3188 [PMID: 
15483230 DOI: 10.1099/vir.0.80401-0]
12 Su AI, Pezacki JP, Wodicka L, Brideau AD, Supekova L, 
Thimme R, Wieland S, Bukh J, Purcell RH, Schultz PG, 
Chisari FV. Genomic analysis of the host response to 
hepatitis C virus infection. Proc Natl Acad Sci USA 2002; 99: 
15669-15674 [PMID: 12441396 DOI: 10.1073/pnas.202608199]
13 Bigger CB, Brasky KM, Lanford RE. DNA microarray 
analysis of chimpanzee liver during acute resolving hepatitis 
C virus infection. J Virol 2001; 75: 7059-7066 [PMID: 11435586 
DOI: 10.1128/JVI.75.15.7059-7066.2001]
14 Bigger CB, Guerra B, Brasky KM, Hubbard G, Beard MR, 
Luxon BA, Lemon SM, Lanford RE. Intrahepatic gene 
expression during chronic hepatitis C virus infection in 
chimpanzees. J Virol 2004; 78: 13779-13792 [PMID: 15564486 
DOI: 10.1128/JVI.78.24.13779-13792.2004]
15 Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, 
Kotenko SV, MacDonald MR, Rice CM. Interferons alpha 
and lambda inhibit hepatitis C virus replication with 
distinct signal transduction and gene regulation kinetics. 
Gastroenterology 2006; 131: 1887-1898 [PMID: 17087946 DOI: 
10.1053/j.gastro.2006.09.052]
16 Olagnier D, Hiscott J. Type I and type III interferon-induced 
immune response: it’s a matter of kinetics and magnitude. 
Hepatology 2014; 59: 1225-1228 [PMID: 24677190 DOI: 
10.1002/hep.26959]
17 McGilvray I, Feld JJ, Chen L, Pattullo V, Guindi M, Fischer 
S, Borozan I, Xie G, Selzner N, Heathcote EJ, Siminovitch 
K. Hepatic cell-type specific gene expression better 
predicts HCV treatment outcome than IL28B genotype. 
Gastroenterology 2012; 142: 1122-1131.e1 [PMID: 22285807 
DOI: 10.1053/j.gastro.2012.01.028]
18 Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, 
Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling MH, 
Albrecht J. Interferon alfa-2b alone or in combination with 
ribavirin for the treatment of relapse of chronic hepatitis 
C. International Hepatitis Interventional Therapy Group. 
N Engl J Med 1998; 339: 1493-1499 [PMID: 9819447 DOI: 
10.1056/NEJM199811193392102]
19 McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee 
WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht 
JK. Interferon alfa-2b alone or in combination with ribavirin 
as initial treatment for chronic hepatitis C. Hepatitis 
Interventional Therapy Group. N Engl J Med 1998; 339: 
1485-1492 [PMID: 9819446 DOI: 10.1056/NEJM199811193392
101]
20 Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, 
Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht 
J. Randomised trial of interferon alpha2b plus ribavirin for 
48 weeks or for 24 weeks versus interferon alpha2b plus 
placebo for 48 weeks for treatment of chronic infection with 
hepatitis C virus. International Hepatitis Interventional 
Therapy Group (IHIT). Lancet 1998; 352: 1426-1432 [PMID: 
9807989]
21 Rauch A, Gaudieri S, Thio C, Bochud PY. Host genetic 
determinants of spontaneous hepatitis C clearance. 
Pharmacogenomics 2009; 10: 1819-1837 [PMID: 19891557 DOI: 
10.2217/pgs.09.121]
22 Macartney MJ, Irish D, Bridge SH, Garcia-Diaz A, Booth CL, 
McCormick AL, Labbett W, Smith C, Velazquez C, Tanwar S, 
Trembling P, Jacobs M, Dusheiko G, Rosenberg W, Haque T. 
Telaprevir or boceprevir based therapy for chronic hepatitis 
C infection: development of resistance-associated variants 
in treatment failure. Antiviral Res 2014; 105: 112-117 [PMID: 
24594347 DOI: 10.1016/j.antiviral.2014.02.019]
23 Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of 
hepatitis C: a systematic review. JAMA 2014; 312: 631-640 
[PMID: 25117132 DOI: 10.1001/jama.2014.7085]
Verstrepen BE et al . Prophylactic HCV vaccines in chimpanzees
65 January 27, 2015|Volume 7|Issue 1|WJH|www.wjgnet.com
24 Izumi N. Efficacy of daclatasvir in hepatitis C virus. Expert 
Rev Anti Infect Ther 2014; 12: 1025-1031 [PMID: 25059552 
DOI: 10.1586/14787210.2014.942282]
25 Wooding S, Jorde LB. Duplication and divergence in 
humans and chimpanzees. Bioessays 2006; 28: 335-338 [PMID: 
16547951 DOI: 10.1002/bies.20385]
26 Altevogt BM, Pankevich DE, Shelton-Davenport MK, Kahn 
JP. Institute of Medicine (US) and National Research Council 
(US) Committee on the Use of Chimpanzees in Biomedical 
and Behavioral Research; Chimpanzees in Biomedical and 
Behavioral Research: Assessing the Necessity. Washington 
(DC): National Academies Press (US), 2011
27 Bettauer RH. Chimpanzees in hepatitis C virus research: 
1998-2007. J Med Primatol 2010; 39: 9-23 [PMID: 19900169 
DOI: 10.1111/j.1600-0684.2009.00390.x]
28 Farci P. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley 
DW, Houghton M. Isolation of a cDNA clone derived from 
a blood-borne non-A, non-B viral hepatitis genome [Science 
1989; 244: 359-362]. J Hepatol 2002; 36: 582-585 [PMID: 
11983439]
29 Walker CM. Comparative features of hepatitis C virus 
infection in humans and chimpanzees. Springer Semin 
Immunopathol 1997; 19: 85-98 [PMID: 9266633]
30 Lanford RE, Bigger C, Bassett S, Klimpel G. The chimpanzee 
model of hepatitis C virus infections. ILAR J 2001; 42: 117-126 
[PMID: 11406714]
31 Netski DM, Mosbruger T, Depla E, Maertens G, Ray SC, 
Hamilton RG, Roundtree S, Thomas DL, McKeating J, Cox 
A. Humoral immune response in acute hepatitis C virus 
infection. Clin Infect Dis 2005; 41: 667-675 [PMID: 16080089 
DOI: 10.1086/432478]
32 Pawlotsky JM. Diagnostic tests for hepatitis C. J Hepatol 
1999; 31 Suppl 1: 71-79 [PMID: 10622564]
33 Bassett SE, Brasky KM, Lanford RE. Analysis of hepatitis C 
virus-inoculated chimpanzees reveals unexpected clinical 
profiles. J Virol 1998; 72: 2589-2599 [PMID: 9525575]
34 Takaki K, Itono Y, Nagafuji A, Naito Y, Shishido T, Takehira 
K, Makioka Y, Taniguchi Y, Fujiwara Y. Three-component 
coupling of acylphosphonates and two carbonyl compounds 
promoted by low-valent samariums: one-Pot synthesis of 
beta-hydroxyphosphonates. J Org Chem 2000; 65: 475-481 
[PMID: 10813960]
35 Koziel MJ, Wong DK, Dudley D, Houghton M, Walker 
BD. Hepatitis C virus-specific cytolytic T lymphocyte and 
T helper cell responses in seronegative persons. J Infect Dis 
1997; 176: 859-866 [PMID: 9333142]
36 Barrett S, Ryan E, Crowe J. Association of the HLA-DRB1*01 
allele with spontaneous viral clearance in an Irish cohort 
infected with hepatitis C virus via contaminated anti-D 
immunoglobulin. J Hepatol 1999; 30: 979-983 [PMID: 10406173]
37 Veerapu NS, Park SH, Tully DC, Allen TM, Rehermann B. 
Trace amounts of sporadically reappearing HCV RNA can 
cause infection. J Clin Invest 2014; 124: 3469-3478 [PMID: 
25003189 DOI: 10.1172/JCI73104]
38 Botarelli P, Brunetto MR, Minutello MA, Calvo P, Unutmaz 
D, Weiner AJ, Choo QL, Shuster JR, Kuo G, Bonino F. 
T-lymphocyte response to hepatitis C virus in different 
clinical courses of infection. Gastroenterology 1993; 104: 
580-587 [PMID: 8425701]
39 Diepolder HM, Zachoval R, Hoffmann RM, Wierenga EA, 
Santantonio T, Jung MC, Eichenlaub D, Pape GR. Possible 
mechanism involving T-lymphocyte response to non-
structural protein 3 in viral clearance in acute hepatitis C 
virus infection. Lancet 1995; 346: 1006-1007 [PMID: 7475549]
40 Ferrari C, Valli A, Galati L, Penna A, Scaccaglia P, Giuberti 
T, Schianchi C, Missale G, Marin MG, Fiaccadori F. T-cell 
response to structural and nonstructural hepatitis C virus 
antigens in persistent and self-limited hepatitis C virus 
infections. Hepatology 1994; 19: 286-295 [PMID: 8294086]
41 Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori 
C, Rumi MG, Houghton M, Fiaccadori F, Ferrari C. Different 
clinical behaviors of acute hepatitis C virus infection are 
associated with different vigor of the anti-viral cell-mediated 
immune response. J Clin Invest 1996; 98: 706-714 [PMID: 
8698862 DOI: 10.1172/JCI118842]
42 Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, 
Chisari FV. Determinants of viral clearance and persistence 
during acute hepatitis C virus infection. J Exp Med 2001; 194: 
1395-1406 [PMID: 11714747]
43 He XS, Rehermann B, López-Labrador FX, Boisvert J, 
Cheung R, Mumm J, Wedemeyer H, Berenguer M, Wright 
TL, Davis MM, Greenberg HB. Quantitative analysis of 
hepatitis C virus-specific CD8(+) T cells in peripheral blood 
and liver using peptide-MHC tetramers. Proc Natl Acad Sci 
USA 1999; 96: 5692-5697 [PMID: 10318946]
44 Schirren CA, Jung MC, Gerlach JT, Worzfeld T, Baretton G, 
Mamin M, Hubert Gruener N, Houghton M, Pape GR. Liver-
derived hepatitis C virus (HCV)-specific CD4(+) T cells 
recognize multiple HCV epitopes and produce interferon 
gamma. Hepatology 2000; 32: 597-603 [PMID: 10960455 DOI: 
10.1053/jhep.2000.9635]
45 Grüner NH, Gerlach TJ, Jung MC, Diepolder HM, Schirren 
CA, Schraut WW, Hoffmann R, Zachoval R, Santantonio T, 
Cucchiarini M, Cerny A, Pape GR. Association of hepatitis 
C virus-specific CD8+ T cells with viral clearance in acute 
hepatitis C. J Infect Dis 2000; 181: 1528-1536 [PMID: 10823750 
DOI: 10.1086/315450]
46 Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, 
Chien DY, Houghton M, Parham P, Walker CM. Analysis 
of a successful immune response against hepatitis C virus. 
Immunity 1999; 10: 439-449 [PMID: 10229187]
47 Dahari H, Feinstone SM, Major ME. Meta-analysis of 
hepatitis C virus vaccine efficacy in chimpanzees indicates an 
importance for structural proteins. Gastroenterology 2010; 139: 
965-974 [PMID: 20621699 DOI: 10.1053/j.gastro.2010.05.077]
48 Bukh J, Forns X, Emerson SU, Purcell RH. Studies of 
hepatitis C virus in chimpanzees and their importance for 
vaccine development. Intervirology 2001; 44: 132-142 [PMID: 
11509874]
49 Abe K, Inchauspe G, Shikata T, Prince AM. Three different 
patterns of hepatitis C virus infection in chimpanzees. 
Hepatology 1992; 15: 690-695 [PMID: 1312987]
50 de Groot NG, Heijmans CM, Zoet YM, de Ru AH, Verreck 
FA, van Veelen PA, Drijfhout JW, Doxiadis GG, Remarque 
EJ, Doxiadis II, van Rood JJ, Koning F, Bontrop RE. AIDS-
protective HLA-B*27/B*57 and chimpanzee MHC class 
I molecules target analogous conserved areas of HIV-1/
SIVcpz. Proc Natl Acad Sci USA 2010; 107: 15175-15180 [PMID: 
20696916 DOI: 10.1073/pnas.1009136107]
51 Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin 
C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, 
Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, 
McHutchison JG, Goldstein DB, Carrington M. Genetic 
variation in IL28B and spontaneous clearance of hepatitis 
C virus. Nature 2009; 461: 798-801 [PMID: 19759533 DOI: 
10.1038/nature08463]
52 Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller 
T, Bochud M, Battegay M, Bernasconi E, Borovicka J, 
Colombo S, Cerny A, Dufour JF, Furrer H, Günthard 
HF, Heim M, Hirschel B, Malinverni R, Moradpour D, 
Müllhaupt B, Witteck A, Beckmann JS, Berg T, Bergmann S, 
Negro F, Telenti A, Bochud PY. Genetic variation in IL28B 
is associated with chronic hepatitis C and treatment failure: 
a genome-wide association study. Gastroenterology 2010; 
138: 1338-1345, 1345.e1-7 [PMID: 20060832 DOI: 10.1053/j.
gastro.2009.12.056]
53 Verstrepen BE, de Groot NG, Groothuismink ZM, Vers-
choor EJ, de Groen RA, Bogers WM, Janssen HL, Mooij P, 
Bontrop RE, Koopman G, Boonstra A. Evaluation of IL-
28B polymorphisms and serum IP-10 in hepatitis C infected 
Verstrepen BE et al . Prophylactic HCV vaccines in chimpanzees
66 January 27, 2015|Volume 7|Issue 1|WJH|www.wjgnet.com
chimpanzees. PLoS One 2012; 7: e46645 [PMID: 23118858 DOI: 
10.1371/journal.pone.0046645]
54 Mehta SH, Cox A, Hoover DR, Wang XH, Mao Q, Ray S, 
Strathdee SA, Vlahov D, Thomas DL. Protection against 
persistence of hepatitis C. Lancet 2002; 359: 1478-1483 [PMID: 
11988247 DOI: 10.1016/S0140-6736(02)08435-0]
55 Osburn WO, Fisher BE, Dowd KA, Urban G, Liu L, Ray 
SC, Thomas DL, Cox AL. Spontaneous control of primary 
hepatitis C virus infection and immunity against persistent 
reinfection. Gastroenterology 2010; 138: 315-324 [PMID: 
19782080 DOI: 10.1053/j.gastro.2009.09.017]
56 Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung 
MC, Ulsenheimer A, Schraut WW, Schirren CA, Waechtler 
M, Backmund M, Pape GR. Acute hepatitis C: high rate of 
both spontaneous and treatment-induced viral clearance. 
Gastroenterology 2003; 125: 80-88 [PMID: 12851873]
57 van de Laar TJ, Molenkamp R, van den Berg C, Schinkel 
J, Beld MG, Prins M, Coutinho RA, Bruisten SM. Frequent 
HCV reinfection and superinfection in a cohort of injecting 
drug users in Amsterdam. J Hepatol 2009; 51: 667-674 [PMID: 
19646773 DOI: 10.1016/j.jhep.2009.05.027]
58 Grebely J, Prins M, Hellard M, Cox AL, Osburn WO, Lauer 
G, Page K, Lloyd AR, Dore GJ. Hepatitis C virus clearance, 
reinfection, and persistence, with insights from studies of 
injecting drug users: towards a vaccine. Lancet Infect Dis 2012; 
12: 408-414 [PMID: 22541630 DOI: 10.1016/S1473-3099(12)700
10-5]
59 Bukh J, Thimme R, Meunier JC, Faulk K, Spangenberg HC, 
Chang KM, Satterfield W, Chisari FV, Purcell RH. Previously 
infected chimpanzees are not consistently protected against 
reinfection or persistent infection after reexposure to the 
identical hepatitis C virus strain. J Virol 2008; 82: 8183-8195 
[PMID: 18550671 DOI: 10.1128/JVI.00142-08]
60 Weiner AJ, Paliard X, Selby MJ, Medina-Selby A, Coit D, 
Nguyen S, Kansopon J, Arian CL, Ng P, Tucker J, Lee CT, 
Polakos NK, Han J, Wong S, Lu HH, Rosenberg S, Brasky 
KM, Chien D, Kuo G, Houghton M. Intrahepatic genetic 
inoculation of hepatitis C virus RNA confers cross-protective 
immunity. J Virol 2001; 75: 7142-7148 [PMID: 11435595 DOI: 
10.1128/JVI.75.15.7142-7148.2001]
61 Bassett SE, Thomas DL, Brasky KM, Lanford RE. Viral 
persistence, antibody to E1 and E2, and hypervariable 
region 1 sequence stability in hepatitis C virus-inoculated 
chimpanzees. J Virol 1999; 73: 1118-1126 [PMID: 9882313]
62 Major ME, Mihalik K, Puig M, Rehermann B, Nascimbeni M, 
Rice CM, Feinstone SM. Previously infected and recovered 
chimpanzees exhibit rapid responses that control hepatitis C 
virus replication upon rechallenge. J Virol 2002; 76: 6586-6595 
[PMID: 12050371]
63 Nascimbeni M, Mizukoshi E, Bosmann M, Major ME, 
Mihalik K, Rice CM, Feinstone SM, Rehermann B. Kinetics of 
CD4+ and CD8+ memory T-cell responses during hepatitis 
C virus rechallenge of previously recovered chimpanzees. J 
Virol 2003; 77: 4781-4793 [PMID: 12663785]
64 Lanford RE, Guerra B, Chavez D, Bigger C, Brasky KM, 
Wang XH, Ray SC, Thomas DL. Cross-genotype immunity 
to hepatitis C virus. J Virol 2004; 78: 1575-1581 [PMID: 
14722311]
65 Prince AM, Brotman B, Lee DH, Pfahler W, Tricoche N, 
Andrus L, Shata MT. Protection against chronic hepatitis C 
virus infection after rechallenge with homologous, but not 
heterologous, genotypes in a chimpanzee model. J Infect Dis 
2005; 192: 1701-1709 [PMID: 16235167 DOI: 10.1086/496889]
66 Shoukry NH, Grakoui A, Houghton M, Chien DY, Ghrayeb 
J, Reimann KA, Walker CM. Memory CD8+ T cells are 
required for protection from persistent hepatitis C virus 
infection. J Exp Med 2003; 197: 1645-1655 [PMID: 12810686 
DOI: 10.1084/jem.20030239]
67 Farci P, Shimoda A, Wong D, Cabezon T, De Gioannis D, 
Strazzera A, Shimizu Y, Shapiro M, Alter HJ, Purcell RH. 
Prevention of hepatitis C virus infection in chimpanzees 
by hyperimmune serum against the hypervariable region 1 
of the envelope 2 protein. Proc Natl Acad Sci USA 1996; 93: 
15394-15399 [PMID: 8986822]
68 Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder 
JC, Strazzera A, Chien DY, Munoz SJ, Balestrieri A, Purcell 
RH, Alter HJ. The outcome of acute hepatitis C predicted 
by the evolution of the viral quasispecies. Science 2000; 288: 
339-344 [PMID: 10764648]
69 Okamoto H, Kojima M, Okada S, Yoshizawa H, Iizuka H, 
Tanaka T, Muchmore EE, Peterson DA, Ito Y, Mishiro S. 
Genetic drift of hepatitis C virus during an 8.2-year infection 
in a chimpanzee: variability and stability. Virology 1992; 190: 
894-899 [PMID: 1325713]
70 van Doorn LJ, Quint W, Tsiquaye K, Voermans J, Paelinck D, 
Kos T, Maertens G, Schellekens H, Murray K. Longitudinal 
analysis of hepatitis C virus infection and genetic drift of the 
hypervariable region. J Infect Dis 1994; 169: 1226-1235 [PMID: 
7545928]
71 Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C 
virus pseudo-particles containing functional E1-E2 envelope 
protein complexes. J Exp Med 2003; 197: 633-642 [PMID: 
12615904]
72 Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, 
Zhao Z, Murthy K, Habermann A, Kräusslich HG, Mizokami 
M, Bartenschlager R, Liang TJ. Production of infectious 
hepatitis C virus in tissue culture from a cloned viral 
genome. Nat Med 2005; 11: 791-796 [PMID: 15951748 DOI: 
10.1038/nm1268]
73 Kato T, Choi Y, Elmowalid G, Sapp RK, Barth H, Furusaka 
A, Mishiro S, Wakita T, Krawczynski K, Liang TJ. Hepatitis 
C virus JFH-1 strain infection in chimpanzees is associated 
with low pathogenicity and emergence of an adaptive 
mutation. Hepatology 2008; 48: 732-740 [PMID: 18712792 DOI: 
10.1002/hep.22422]
74 Lohmann V, Bartenschlager R. On the history of hepatitis 
C virus cell culture systems. J Med Chem 2014; 57: 1627-1642 
[PMID: 24164647 DOI: 10.1021/jm401401n]
75 Sabahi A. Hepatitis C Virus entry: the early steps in the viral 
replication cycle. Virol J 2009; 6: 117 [PMID: 19643019 DOI: 
10.1186/1743-422X-6-117]
76 Johansson DX, Voisset C, Tarr AW, Aung M, Ball JK, 
Dubuisson J, Persson MA. Human combinatorial libraries 
yield rare antibodies that broadly neutralize hepatitis C 
virus. Proc Natl Acad Sci USA 2007; 104: 16269-16274 [PMID: 
17911260 DOI: 10.1073/pnas.0705522104]
77 Kato N, Sekiya H, Ootsuyama Y, Nakazawa T, Hijikata M, 
Ohkoshi S, Shimotohno K. Humoral immune response to 
hypervariable region 1 of the putative envelope glycoprotein 
(gp70) of hepatitis C virus. J Virol 1993; 67: 3923-3930 [PMID: 
7685404]
78 Keck ZY, Li TK, Xia J, Gal-Tanamy M, Olson O, Li SH, 
Patel AH, Ball JK, Lemon SM, Foung SK. Definition of a 
conserved immunodominant domain on hepatitis C virus E2 
glycoprotein by neutralizing human monoclonal antibodies. 
J Virol 2008; 82: 6061-6066 [PMID: 18400849 DOI: 10.1128/
JVI.02475-07]
79 Meunier JC, Russell RS, Goossens V, Priem S, Walter H, 
Depla E, Union A, Faulk KN, Bukh J, Emerson SU, Purcell 
RH. Isolation and characterization of broadly neutralizing 
human monoclonal antibodies to the e1 glycoprotein of 
hepatitis C virus. J Virol 2008; 82: 966-973 [PMID: 17977972 
DOI: 10.1128/JVI.01872-07]
80 Owsianka A, Tarr AW, Juttla VS, Lavillette D, Bartosch B, 
Cosset FL, Ball JK, Patel AH. Monoclonal antibody AP33 
defines a broadly neutralizing epitope on the hepatitis C 
virus E2 envelope glycoprotein. J Virol 2005; 79: 11095-11104 
[PMID: 16103160 DOI: 10.1128/JVI.79.17.11095-11104.2005]
81 Perotti M, Mancini N, Diotti RA, Tarr AW, Ball JK, 
Owsianka A, Adair R, Patel AH, Clementi M, Burioni R. 
Verstrepen BE et al . Prophylactic HCV vaccines in chimpanzees
67 January 27, 2015|Volume 7|Issue 1|WJH|www.wjgnet.com
Identification of a broadly cross-reacting and neutralizing 
human monoclonal antibody directed against the hepatitis C 
virus E2 protein. J Virol 2008; 82: 1047-1052 [PMID: 17989176 
DOI: 10.1128/JVI.01986-07]
82 Shimizu YK, Igarashi H, Kiyohara T, Cabezon T, Farci P, 
Purcell RH, Yoshikura H. A hyperimmune serum against a 
synthetic peptide corresponding to the hypervariable region 
1 of hepatitis C virus can prevent viral infection in cell 
cultures. Virology 1996; 223: 409-412 [PMID: 8806581 DOI: 
10.1006/viro.1996.0497]
83 Bartosch B, Bukh J, Meunier JC, Granier C, Engle RE, 
Blackwelder WC, Emerson SU, Cosset FL, Purcell RH. In vitro 
assay for neutralizing antibody to hepatitis C virus: evidence 
for broadly conserved neutralization epitopes. Proc Natl 
Acad Sci USA 2003; 100: 14199-14204 [PMID: 14617769 DOI: 
10.1073/pnas.2335981100]
84 Vieyres G, Dubuisson J, Patel AH. Characterization of 
antibody-mediated neutralization directed against the 
hypervariable region 1 of hepatitis C virus E2 glycoprotein. 
J Gen Virol 2011; 92: 494-506 [PMID: 21084495 DOI: 10.1099/
vir.0.028092-0]
85 Broering TJ, Garrity KA, Boatright NK, Sloan SE, Sandor 
F, Thomas WD, Szabo G, Finberg RW, Ambrosino DM, 
Babcock GJ. Identification and characterization of broadly 
neutralizing human monoclonal antibodies directed against 
the E2 envelope glycoprotein of hepatitis C virus. J Virol 2009; 
83: 12473-12482 [PMID: 19759151 DOI: 10.1128/JVI.01138-09]
86 Tarr AW, Owsianka AM, Timms JM, McClure CP, Brown 
RJ, Hickling TP, Pietschmann T, Bartenschlager R, Patel AH, 
Ball JK. Characterization of the hepatitis C virus E2 epitope 
defined by the broadly neutralizing monoclonal antibody 
AP33. Hepatology 2006; 43: 592-601 [PMID: 16496330 DOI: 
10.1002/hep.21088]
87 Wahid A, Dubuisson J. Virus-neutralizing antibodies to 
hepatitis C virus. J Viral Hepat 2013; 20: 369-376 [PMID: 
23647953 DOI: 10.1111/jvh.12094]
88 Lavillette D, Morice Y, Germanidis G, Donot P, Soulier A, 
Pagkalos E, Sakellariou G, Intrator L, Bartosch B, Pawlotsky 
JM, Cosset FL. Human serum facilitates hepatitis C virus 
infection, and neutralizing responses inversely correlate 
with viral replication kinetics at the acute phase of hepatitis 
C virus infection. J Virol 2005; 79: 6023-6034 [PMID: 15857988 
DOI: 10.1128/JVI.79.10.6023-6034.2005]
89 Logvinoff C, Major ME, Oldach D, Heyward S, Talal A, Balfe P, 
Feinstone SM, Alter H, Rice CM, McKeating JA. Neutralizing 
antibody response during acute and chronic hepatitis C virus 
infection. Proc Natl Acad Sci USA 2004; 101: 10149-10154 [PMID: 
15220475 DOI: 10.1073/pnas.0403519101]
90 Razvi S, Schneider L, Jonas MM, Cunningham-Rundles 
C. Outcome of intravenous immunoglobulin-transmitted 
hepatitis C virus infection in primary immunodeficiency. 
Clin Immunol 2001; 101: 284-288 [PMID: 11726220 DOI: 
10.1006/clim.2001.5132]
91 Grakoui A, Shoukry NH, Woollard DJ, Han JH, Hanson 
HL, Ghrayeb J, Murthy KK, Rice CM, Walker CM. HCV 
persistence and immune evasion in the absence of memory 
T cell help. Science 2003; 302: 659-662 [PMID: 14576438 DOI: 
10.1126/science.1088774]
92 Klenerman P, Thimme R. T cell responses in hepatitis C: 
the good, the bad and the unconventional. Gut 2012; 61: 
1226-1234 [PMID: 21873736 DOI: 10.1136/gutjnl-2011-300620]
93 Bowen DG, Walker CM. Adaptive immune responses in 
acute and chronic hepatitis C virus infection. Nature 2005; 
436: 946-952 [PMID: 16107834 DOI: 10.1038/nature04079]
94 Abdel-Hakeem MS, Shoukry NH. Protective immunity 
against hepatitis C: many shades of gray. Front Immunol 2014; 
5: 274 [PMID: 24982656 DOI: 10.3389/fimmu.2014.00274]
95 Claassen MA, Janssen HL, Boonstra A. Role of T cell 
immunity in hepatitis C virus infections. Curr Opin Virol 2013; 
3: 461-467 [PMID: 23735335 DOI: 10.1016/j.coviro.2013.05.006]
96 Timm J, Lauer GM, Kavanagh DG, Sheridan I, Kim AY, 
Lucas M, Pillay T, Ouchi K, Reyor LL, Schulze zur Wiesch J, 
Gandhi RT, Chung RT, Bhardwaj N, Klenerman P, Walker 
BD, Allen TM. CD8 epitope escape and reversion in acute 
HCV infection. J Exp Med 2004; 200: 1593-1604 [PMID: 
15611288 DOI: 10.1084/jem.20041006]
97 Fukuda R, Ishimura N, Nguyen XT, Chowdhury A, Ishihara 
S, Sakai S, Akagi S, Tokuda A, Watanabe M, Fukumoto S. 
Gene expression of perforin and granzyme A in the liver 
in chronic hepatitis C: comparison with peripheral blood 
mononuclear cells. Microbiol Immunol 1995; 39: 873-877 
[PMID: 8657014]
98 Lauer GM, Lucas M, Timm J, Ouchi K, Kim AY, Day CL, 
Schulze Zur Wiesch J, Paranhos-Baccala G, Sheridan I, 
Casson DR, Reiser M, Gandhi RT, Li B, Allen TM, Chung 
RT, Klenerman P, Walker BD. Full-breadth analysis of CD8+ 
T-cell responses in acute hepatitis C virus infection and early 
therapy. J Virol 2005; 79: 12979-12988 [PMID: 16189000 DOI: 
10.1128/JVI.79.20.12979-12988.2005]
99 Cox AL, Mosbruger T, Lauer GM, Pardoll D, Thomas DL, 
Ray SC. Comprehensive analyses of CD8+ T cell responses 
during longitudinal study of acute human hepatitis C. 
Hepatology 2005; 42: 104-112 [PMID: 15962289 DOI: 10.1002/
hep.20749]
100 Urbani S, Amadei B, Fisicaro P, Tola D, Orlandini A, 
Sacchelli L, Mori C, Missale G, Ferrari C. Outcome of acute 
hepatitis C is related to virus-specific CD4 function and 
maturation of antiviral memory CD8 responses. Hepatology 
2006; 44: 126-139 [PMID: 16799989 DOI: 10.1002/hep.21242]
101 Watanabe H, Wells F, Major ME. Clearance of hepatitis C in 
chimpanzees is associated with intrahepatic T-cell perforin 
expression during the late acute phase. J Viral Hepat 2010; 17: 
245-253 [PMID: 19709361 DOI: 10.1111/j.1365-2893.2009.0117
2.x]
102 Scottà C, Garbuglia AR, Ruggeri L, Spada E, Laurenti L, 
Perrone MP, Girelli G, Mele A, Capobianchi MR, Folgori 
A, Nicosia A, Del Porto P, Piccolella E. Influence of specific 
CD4+ T cells and antibodies on evolution of hypervariable 
region 1 during acute HCV infection. J Hepatol 2008; 48: 
216-228 [PMID: 18180071 DOI: 10.1016/j.jhep.2007.09.011]
103 Diepolder HM, Zachoval R, Hoffmann RM, Jung MC, 
Gerlach T, Pape GR. The role of hepatitis C virus specific 
CD4+ T lymphocytes in acute and chronic hepatitis C. J Mol 
Med (Berl) 1996; 74: 583-588 [PMID: 8912179]
104 Schulze Zur Wiesch J, Ciuffreda D, Lewis-Ximenez L, 
Kasprowicz V, Nolan BE, Streeck H, Aneja J, Reyor LL, Allen 
TM, Lohse AW, McGovern B, Chung RT, Kwok WW, Kim 
AY, Lauer GM. Broadly directed virus-specific CD4+ T cell 
responses are primed during acute hepatitis C infection, but 
rapidly disappear from human blood with viral persistence. 
J Exp Med 2012; 209: 61-75 [PMID: 22213804 DOI: 10.1084/
jem.20100388]
105 Hakim MS, Spaan M, Janssen HL, Boonstra A. Inhibitory 
receptor molecules in chronic hepatitis B and C infections: 
novel targets for immunotherapy? Rev Med Virol 2014; 24: 
125-138 [PMID: 24757728]
106 Choo QL, Kuo G, Ralston R, Weiner A, Chien D, Van Nest 
G, Han J, Berger K, Thudium K, Kuo C. Vaccination of 
chimpanzees against infection by the hepatitis C virus. Proc 
Natl Acad Sci USA 1994; 91: 1294-1298 [PMID: 7509068]
107 Coates S CQ-L, Kuo G, Crawford K, Dong C, Wininger M, 
Houghton M. Protection of chimpanzees against heterologous 
1a viral challenge using a gpE1/gpE2 heterodimer vaccine. 
Jilbert AR, Gragacic EVL, Vickery K, Burrell C, Cossart YE, 
editors. Proceedings of the 11th international symposium on 
viral hepatitis and liver disease, 2003: 118-123
108 Esumi M, Rikihisa T, Nishimura S, Goto J, Mizuno K, 
Zhou YH, Shikata T. Experimental vaccine activities of 
recombinant E1 and E2 glycoproteins and hypervariable 
region 1 peptides of hepatitis C virus in chimpanzees. Arch 
Verstrepen BE et al . Prophylactic HCV vaccines in chimpanzees
68 January 27, 2015|Volume 7|Issue 1|WJH|www.wjgnet.com
Virol 1999; 144: 973-980 [PMID: 10416378]
109 Verstrepen BE, Depla E, Rollier CS, Mares G, Drexhage JA, 
Priem S, Verschoor EJ, Koopman G, Granier C, Dreux M, 
Cosset FL, Maertens G, Heeney JL. Clearance of genotype 1b 
hepatitis C virus in chimpanzees in the presence of vaccine-
induced E1-neutralizing antibodies. J Infect Dis 2011; 204: 
837-844 [PMID: 21849281 DOI: 10.1093/infdis/jir423]
110 Forns X, Payette PJ, Ma X, Satterfield W, Eder G, Mushahwar 
IK, Govindarajan S, Davis HL, Emerson SU, Purcell RH, 
Bukh J. Vaccination of chimpanzees with plasmid DNA 
encoding the hepatitis C virus (HCV) envelope E2 protein 
modified the infection after challenge with homologous 
monoclonal HCV. Hepatology 2000; 32: 618-625 [PMID: 
10960458 DOI: 10.1053/jhep.2000.9877]
111 Elmowalid GA, Qiao M, Jeong SH, Borg BB, Baumert TF, Sapp 
RK, Hu Z, Murthy K, Liang TJ. Immunization with hepatitis 
C virus-like particles results in control of hepatitis C virus 
infection in chimpanzees. Proc Natl Acad Sci USA 2007; 104: 
8427-8432 [PMID: 17485666 DOI: 10.1073/pnas.0702162104]
112 Rollier C, Depla E, Drexhage JA, Verschoor EJ, Verstrepen 
BE, Fatmi A, Brinster C, Fournillier A, Whelan JA, Whelan 
M, Jacobs D, Maertens G, Inchauspé G, Heeney JL. Control 
of heterologous hepatitis C virus infection in chimpanzees 
is associated with the quality of vaccine-induced peripheral 
T-helper immune response. J Virol 2004; 78: 187-196 [PMID: 
14671100]
113 Puig M, Major ME, Mihalik K, Feinstone SM. Immunization 
of chimpanzees with an envelope protein-based vaccine 
enhances specific humoral and cellular immune responses 
that delay hepatitis C virus infection. Vaccine 2004; 22: 
991-1000 [PMID: 15161076 DOI: 10.1016/j.vaccine.2003.09.010]
114 Puig M, Mihalik K, Tilton JC, Williams O, Merchlinsky 
M, Connors M, Feinstone SM, Major ME. CD4+ immune 
escape and subsequent T-cell failure following chimpanzee 
immunization against hepatitis C virus. Hepatology 2006; 44: 
736-745 [PMID: 16941702 DOI: 10.1002/hep.21319]
115 Rollier CS, Paranhos-Baccala G, Verschoor EJ, Verstrepen 
BE, Drexhage JA, Fagrouch Z, Berland JL, Komurian-
Pradel F, Duverger B, Himoudi N, Staib C, Meyr M, Whelan 
M, Whelan JA, Adams VC, Larrea E, Riezu JI, Lasarte JJ, 
Bartosch B, Cosset FL, Spaan WJ, Diepolder HM, Pape GR, 
Sutter G, Inchauspe G, Heeney JL. Vaccine-induced early 
control of hepatitis C virus infection in chimpanzees fails to 
impact on hepatic PD-1 and chronicity. Hepatology 2007; 45: 
602-613 [PMID: 17326154 DOI: 10.1002/hep.21573]
116 Youn JW, Hu YW, Tricoche N, Pfahler W, Shata MT, Dreux 
M, Cosset FL, Folgori A, Lee DH, Brotman B, Prince AM. 
Evidence for protection against chronic hepatitis C virus 
infection in chimpanzees by immunization with replicating 
recombinant vaccinia virus. J Virol 2008; 82: 10896-10905 
[PMID: 18753204 DOI: 10.1128/JVI.01179-08]
117 Youn JW, Park SH, Lavillette D, Cosset FL, Yang SH, Lee 
CG, Jin HT, Kim CM, Shata MT, Lee DH, Pfahler W, Prince 
AM, Sung YC. Sustained E2 antibody response correlates 
with reduced peak viremia after hepatitis C virus infection 
in the chimpanzee. Hepatology 2005; 42: 1429-1436 [PMID: 
16317673 DOI: 10.1002/hep.20934]
118 Folgori A, Capone S, Ruggeri L, Meola A, Sporeno E, 
Ercole BB, Pezzanera M, Tafi R, Arcuri M, Fattori E, Lahm 
A, Luzzago A, Vitelli A, Colloca S, Cortese R, Nicosia A. 
A T-cell HCV vaccine eliciting effective immunity against 
heterologous virus challenge in chimpanzees. Nat Med 2006; 
12: 190-197 [PMID: 16462801 DOI: 10.1038/nm1353]
119 Frey SE, Houghton M, Coates S, Abrignani S, Chien D, 
Rosa D, Pileri P, Ray R, Di Bisceglie AM, Rinella P, Hill 
H, Wolff MC, Schultze V, Han JH, Scharschmidt B, Belshe 
RB. Safety and immunogenicity of HCV E1E2 vaccine 
adjuvanted with MF59 administered to healthy adults. 
Vaccine 2010; 28: 6367-6373 [PMID: 20619382 DOI: 10.1016/
j.vaccine.2010.06.084]
120 Zubkova I, Duan H, Wells F, Mostowski H, Chang E, 
Pirollo K, Krawczynski K, Lanford R, Major M. Hepatitis 
C virus clearance correlates with HLA-DR expression on 
proliferating CD8+ T cells in immune-primed chimpanzees. 
Hepatology 2014; 59: 803-813 [PMID: 24123114 DOI: 10.1002/
hep.26747]
121 Drummer HE. Challenges to the development of vaccines 
to hepatitis C virus that elicit neutralizing antibodies. 
Front Microbiol 2014; 5: 329 [PMID: 25071742 DOI: 10.3389/
fmicb.2014.00329]
122 Kim CW, Chang KM. Hepatitis C virus: virology and life 
cycle. Clin Mol Hepatol 2013; 19: 17-25 [PMID: 23593605 DOI: 
10.3350/cmh.2013.19.1.17]
123 Vieyres G, Thomas X, Descamps V, Duverlie G, Patel AH, 
Dubuisson J. Characterization of the envelope glycoproteins 
associated with infectious hepatitis C virus. J Virol 2010; 84: 
10159-10168 [PMID: 20668082 DOI: 10.1128/JVI.01180-10]
124 Krey T, d’Alayer J, Kikuti CM, Saulnier A, Damier-Piolle 
L, Petitpas I, Johansson DX, Tawar RG, Baron B, Robert B, 
England P, Persson MA, Martin A, Rey FA. The disulfide 
bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary 
organization of the molecule. PLoS Pathog 2010; 6: e1000762 
[PMID: 20174556 DOI: 10.1371/journal.ppat.1000762]
125 Sautto G, Tarr AW, Mancini N, Clementi M. Structural and 
antigenic definition of hepatitis C virus E2 glycoprotein 
epitopes targeted by monoclonal antibodies. Clin Dev Immunol 
2013; 2013: 450963 [PMID: 23935648 DOI: 10.1155/2013/450963]
126 Brazzoli M, Helenius A, Foung SK, Houghton M, Abrignani 
S, Merola M. Folding and dimerization of hepatitis C virus 
E1 and E2 glycoproteins in stably transfected CHO cells. 
Virology 2005; 332: 438-453 [PMID: 15661174 DOI: 10.1016/
j.virol.2004.11.034]
127 Lavillette D, Pécheur EI, Donot P, Fresquet J, Molle J, 
Corbau R, Dreux M, Penin F, Cosset FL. Characterization 
of fusion determinants points to the involvement of three 
discrete regions of both E1 and E2 glycoproteins in the 
membrane fusion process of hepatitis C virus. J Virol 2007; 
81: 8752-8765 [PMID: 17537855 DOI: 10.1128/JVI.02642-06]
128 Meunier JC, Gottwein JM, Houghton M, Russell RS, 
Emerson SU, Bukh J, Purcell RH. Vaccine-induced cross-
genotype reactive neutralizing antibodies against hepatitis C 
virus. J Infect Dis 2011; 204: 1186-1190 [PMID: 21917891 DOI: 
10.1093/infdis/jir511]
129 Koup RA, Douek DC. Vaccine design for CD8 T lymphocyte 
responses. Cold Spring Harb Perspect Med 2011; 1: a007252 
[PMID: 22229122 DOI: 10.1101/cshperspect.a007252]
130 Roldão A, Mellado MC, Castilho LR, Carrondo MJ, Alves 
PM. Virus-like particles in vaccine development. Expert Rev 
Vaccines 2010; 9: 1149-1176 [PMID: 20923267 DOI: 10.1586/
erv.10.115]
131 Paris RM, Kim JH, Robb ML, Michael NL. Prime-boost 
immunization with poxvirus or adenovirus vectors as a 
strategy to develop a protective vaccine for HIV-1. Expert Rev 
Vaccines 2010; 9: 1055-1069 [PMID: 20822348 DOI: 10.1586/
erv.10.106]
132 Verstrepen BE, Verschoor EJ, Fagrouch ZC, Mooij P, de 
Groot NG, Bontrop RE, Bogers WM, Heeney JL, Koopman G. 
Strong vaccine-induced CD8 T-cell responses have cytolytic 
function in a chimpanzee clearing HCV infection. PLoS 
One 2014; 9: e95103 [PMID: 24740375 DOI: 10.1371/journal.
pone.0095103]
133 Schmitz V, Qian C, Ruiz J, Sangro B, Melero I, Mazzolini 
G, Narvaiza I, Prieto J. Gene therapy for liver diseases: 
recent strategies for treatment of viral hepatitis and liver 
malignancies. Gut 2002; 50: 130-135 [PMID: 11772981]
134 Zubkova I, Choi YH, Chang E, Pirollo K, Uren T, Watanabe 
H, Wells F, Kachko A, Krawczynski K, Major ME. T-cell 
vaccines that elicit effective immune responses against HCV 
in chimpanzees may create greater immune pressure for 
viral mutation. Vaccine 2009; 27: 2594-2602 [PMID: 19428866 
Verstrepen BE et al . Prophylactic HCV vaccines in chimpanzees
69 January 27, 2015|Volume 7|Issue 1|WJH|www.wjgnet.com
DOI: 10.1016/j.vaccine.2009.02.045]
135 Claassen MA, de Knegt RJ, Turgut D, Groothuismink ZM, 
Janssen HL, Boonstra A. Negative regulation of hepatitis 
C virus specific immunity is highly heterogeneous and 
modulated by pegylated interferon-alpha/ribavirin therapy. 
PLoS One 2012; 7: e49389 [PMID: 23145169 DOI: 10.1371/
journal.pone.0049389]
136 Söderholm J, Ahlén G, Kaul A, Frelin L, Alheim M, Barnfield 
C, Liljeström P, Weiland O, Milich DR, Bartenschlager R, 
Sällberg M. Relation between viral fitness and immune 
escape within the hepatitis C virus protease. Gut 2006; 55: 
266-274 [PMID: 16105887 DOI: 10.1136/gut.2005.072231]
137 Brown RJ, Hudson N, Wilson G, Rehman SU, Jabbari S, Hu 
K, Tarr AW, Borrow P, Joyce M, Lewis J, Zhu LF, Law M, 
Kneteman N, Tyrrell DL, McKeating JA, Ball JK. Hepatitis C 
virus envelope glycoprotein fitness defines virus population 
composition following transmission to a new host. J Virol 
2012; 86: 11956-11966 [PMID: 22855498 DOI: 10.1128/
JVI.01079-12]
138 Fafi-Kremer S, Fofana I, Soulier E, Carolla P, Meuleman P, 
Leroux-Roels G, Patel AH, Cosset FL, Pessaux P, Doffoël M, 
Wolf P, Stoll-Keller F, Baumert TF. Viral entry and escape 
from antibody-mediated neutralization influence hepatitis C 
virus reinfection in liver transplantation. J Exp Med 2010; 207: 
2019-2031 [PMID: 20713596 DOI: 10.1084/jem.20090766]
139 Bengsch B, Seigel B, Ruhl M, Timm J, Kuntz M, Blum HE, 
Pircher H, Thimme R. Coexpression of PD-1, 2B4, CD160 and 
KLRG1 on exhausted HCV-specific CD8+ T cells is linked to 
antigen recognition and T cell differentiation. PLoS Pathog 
2010; 6: e1000947 [PMID: 20548953 DOI: 10.1371/journal.
ppat.1000947]
140 Rutebemberwa A, Ray SC, Astemborski J, Levine J, Liu L, 
Dowd KA, Clute S, Wang C, Korman A, Sette A, Sidney J, 
Pardoll DM, Cox AL. High-programmed death-1 levels on 
hepatitis C virus-specific T cells during acute infection are 
associated with viral persistence and require preservation 
of cognate antigen during chronic infection. J Immunol 2008; 
181: 8215-8225 [PMID: 19050238]
141 Kasprowicz V, Schulze Zur Wiesch J, Kuntzen T, Nolan 
BE, Longworth S, Berical A, Blum J, McMahon C, Reyor LL, 
Elias N, Kwok WW, McGovern BG, Freeman G, Chung RT, 
Klenerman P, Lewis-Ximenez L, Walker BD, Allen TM, Kim 
AY, Lauer GM. High level of PD-1 expression on hepatitis C 
virus (HCV)-specific CD8+ and CD4+ T cells during acute 
HCV infection, irrespective of clinical outcome. J Virol 2008; 
82: 3154-3160 [PMID: 18160439 DOI: 10.1128/JVI.02474-07]
142 McMahan RH, Golden-Mason L, Nishimura MI, McMahon 
BJ, Kemper M, Allen TM, Gretch DR, Rosen HR. Tim-3 
expression on PD-1+ HCV-specific human CTLs is 
associated with viral persistence, and its blockade restores 
hepatocyte-directed in vitro cytotoxicity. J Clin Invest 2010; 
120: 4546-4557 [PMID: 21084749 DOI: 10.1172/JCI43127]
143 Golden-Mason L, Palmer BE, Kassam N, Townshend-Bulson 
L, Livingston S, McMahon BJ, Castelblanco N, Kuchroo V, 
Gretch DR, Rosen HR. Negative immune regulator Tim-3 is 
overexpressed on T cells in hepatitis C virus infection and 
its blockade rescues dysfunctional CD4+ and CD8+ T cells. 
J Virol 2009; 83: 9122-9130 [PMID: 19587053 DOI: 10.1128/
JVI.00639-09]
144 Belkaid Y. Regulatory T cells and infection: a dangerous 
necessity. Nat Rev Immunol 2007; 7: 875-888 [PMID: 17948021 
DOI: 10.1038/nri2189]
145 Sangro B, Gomez-Martin C, de la Mata M, Iñarrairaegui 
M, Garralda E, Barrera P, Riezu-Boj JI, Larrea E, Alfaro C, 
Sarobe P, Lasarte JJ, Pérez-Gracia JL, Melero I, Prieto J. A 
clinical trial of CTLA-4 blockade with tremelimumab in 
patients with hepatocellular carcinoma and chronic hepatitis 
C. J Hepatol 2013; 59: 81-88 [PMID: 23466307 DOI: 10.1016/j.
jhep.2013.02.022]
146 Fuller MJ, Callendret B, Zhu B, Freeman GJ, Hasselschwert 
DL, Satterfield W, Sharpe AH, Dustin LB, Rice CM, Grakoui 
A, Ahmed R, Walker CM. Immunotherapy of chronic hepatitis 
C virus infection with antibodies against programmed cell 
death-1 (PD-1). Proc Natl Acad Sci USA 2013; 110: 15001-15006 
[PMID: 23980172 DOI: 10.1073/pnas.1312772110]
147 Raziorrouh B, Ulsenheimer A, Schraut W, Heeg M, Kurkts-
chiev P, Zachoval R, Jung MC, Thimme R, Neumann-Haefelin 
C, Horster S, Wächtler M, Spannagl M, Haas J, Diepolder HM, 
Grüner NH. Inhibitory molecules that regulate expansion 
and restoration of HCV-specific CD4+ T cells in patients with 
chronic infection. Gastroenterology 2011; 141: 1422-1431, 1431.
e1-6 [PMID: 21763239 DOI: 10.1053/j.gastro.2011.07.004]
148 Nellore A, Fishman JA. NK cells, innate immunity and 
hepatitis C infection after liver transplantation. Clin Infect Dis 
2011; 52: 369-377 [PMID: 21217184 DOI: 10.1093/cid/ciq156]
149 Leroux-Roels G, Depla E, Hulstaert F, Tobback L, Dincq S, 
Desmet J, Desombere I, Maertens G. A candidate vaccine based 
on the hepatitis C E1 protein: tolerability and immunogenicity 
in healthy volunteers. Vaccine 2004; 22: 3080-3086 [PMID: 
15297058 DOI: 10.1016/j.vaccine.2004.02.002]
P- Reviewer: Irshad M, Lichtor T, Qiu HJ, 
Robaeys GKMM, Tabarkiewicz J 
S- Editor: Ji FF    L- Editor: A    E- Editor: Liu SQ 
Verstrepen BE et al . Prophylactic HCV vaccines in chimpanzees
                                      © 2015 Baishideng Publishing Group Inc. All rights reserved.
Published by Baishideng Publishing Group Inc
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
http://www.wjgnet.com
